Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Aaron Seth Kesselheim, M.D.

Co-Author

This page shows the publications co-authored by Aaron Kesselheim and Jessica Franklin.
Connection Strength

6.985
  1. Two decades of new drug development for central nervous system disorders. Nat Rev Drug Discov. 2015 Dec; 14(12):815-6.
    View in: PubMed
    Score: 0.658
  2. Distributions of industry payments to Massachusetts physicians. N Engl J Med. 2013 May 30; 368(22):2049-52.
    View in: PubMed
    Score: 0.551
  3. A randomized study of how physicians interpret research funding disclosures. N Engl J Med. 2012 Sep 20; 367(12):1119-27.
    View in: PubMed
    Score: 0.264
  4. The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS One. 2012; 7(2):e31894.
    View in: PubMed
    Score: 0.254
  5. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA. 2011 Jun 08; 305(22):2320-6.
    View in: PubMed
    Score: 0.242
  6. A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises. J Natl Cancer Inst. 2020 04 01; 112(4):335-342.
    View in: PubMed
    Score: 0.223
  7. Public Approval of Exception From Informed Consent in Emergency Clinical Trials: A Systematic Review of Community Consultation Surveys. JAMA Netw Open. 2019 07 03; 2(7):e197591.
    View in: PubMed
    Score: 0.211
  8. Impact Of The Priority Review Voucher Program On Drug Development For Rare Pediatric Diseases. Health Aff (Millwood). 2019 02; 38(2):313-319.
    View in: PubMed
    Score: 0.205
  9. Application and Impact of Run-In Studies for the Evaluation of Statin Efficacy and Safety. J Gen Intern Med. 2018 06; 33(6):792-794.
    View in: PubMed
    Score: 0.196
  10. Application and impact of run-in studies. J Gen Intern Med. 2018 05; 33(5):759-763.
    View in: PubMed
    Score: 0.192
  11. Association of the Priority Review Voucher With Neglected Tropical Disease Drug and Vaccine Development. JAMA. 2017 07 25; 318(4):388-389.
    View in: PubMed
    Score: 0.185
  12. Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors. Circ Cardiovasc Qual Outcomes. 2017 Jun; 10(6).
    View in: PubMed
    Score: 0.183
  13. Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development. Clin Pharmacol Ther. 2017 Aug; 102(2):290-296.
    View in: PubMed
    Score: 0.183
  14. The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine. PLoS One. 2017; 12(4):e0175313.
    View in: PubMed
    Score: 0.181
  15. Do patients trust the FDA?: a survey assessing how patients view the generic drug approval process. Pharmacoepidemiol Drug Saf. 2017 Jun; 26(6):694-701.
    View in: PubMed
    Score: 0.181
  16. Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. JAMA Intern Med. 2016 Dec 01; 176(12):1826-1833.
    View in: PubMed
    Score: 0.177
  17. Physicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug Approval. PLoS One. 2016; 11(10):e0163339.
    View in: PubMed
    Score: 0.175
  18. Payments to Physicians, Prescribing Rates, and More Appropriate Conclusions-Reply. JAMA Intern Med. 2016 10 01; 176(10):1577.
    View in: PubMed
    Score: 0.175
  19. Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012. JACC Basic Transl Sci. 2016 Aug; 1(5):301-308.
    View in: PubMed
    Score: 0.173
  20. Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort study. BMJ. 2016 Jun 28; 353:i3323.
    View in: PubMed
    Score: 0.171
  21. Prevalence and Predictors of Generic Drug Skepticism Among Physicians: Results of a National Survey. JAMA Intern Med. 2016 06 01; 176(6):845-7.
    View in: PubMed
    Score: 0.171
  22. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts. JAMA Intern Med. 2016 06 01; 176(6):763-8.
    View in: PubMed
    Score: 0.171
  23. Physicians' Knowledge About FDA Approval Standards and Perceptions of the "Breakthrough Therapy" Designation. JAMA. 2016 Apr 12; 315(14):1516-8.
    View in: PubMed
    Score: 0.169
  24. Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis. PLoS One. 2016; 11(3):e0152195.
    View in: PubMed
    Score: 0.169
  25. Variations in Patients' Perceptions and Use of Generic Drugs: Results of a National Survey. J Gen Intern Med. 2016 06; 31(6):609-14.
    View in: PubMed
    Score: 0.167
  26. Medical Schools' Industry Interaction Policies Not Associated With Trainees' Self-Reported Behavior as Residents: Results of a National Survey. J Grad Med Educ. 2015 Dec; 7(4):595-602.
    View in: PubMed
    Score: 0.165
  27. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. BMJ. 2015 Sep 23; 351:h4633.
    View in: PubMed
    Score: 0.163
  28. Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population. J Gen Intern Med. 2015 Nov; 30(11):1633-8.
    View in: PubMed
    Score: 0.158
  29. Association of medical students' reports of interactions with the pharmaceutical and medical device industries and medical school policies and characteristics: a cross-sectional study. PLoS Med. 2014 Oct; 11(10):e1001743.
    View in: PubMed
    Score: 0.152
  30. Association of marketing interactions with medical trainees' knowledge about evidence-based prescribing: results from a national survey. JAMA Intern Med. 2014 Aug; 174(8):1283-90.
    View in: PubMed
    Score: 0.150
  31. Physician trainees' interactions with the pharmaceutical industry. J Gen Intern Med. 2013 Oct; 28(10):1267.
    View in: PubMed
    Score: 0.142
  32. Changing interactions between physician trainees and the pharmaceutical industry: a national survey. J Gen Intern Med. 2013 Aug; 28(8):1064-71.
    View in: PubMed
    Score: 0.140
  33. Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs. BMJ Qual Saf. 2013 Sep; 22(9):727-34.
    View in: PubMed
    Score: 0.138
  34. Impact of State Laws Restricting Opioid Duration on Characteristics of New Opioid Prescriptions. J Gen Intern Med. 2019 11; 34(11):2339-2341.
    View in: PubMed
    Score: 0.054
  35. Changes in Outpatient Use of Antibiotics by Adults in the United States, 2006-2015. Drug Saf. 2018 12; 41(12):1333-1342.
    View in: PubMed
    Score: 0.051
  36. Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines. J Clin Oncol. 2018 06 20; 36(18):1805-1812.
    View in: PubMed
    Score: 0.049
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.